These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

883 related items for PubMed ID: 25313916

  • 1. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.
    Tavori H, Giunzioni I, Linton MF, Fazio S.
    Circ Res; 2013 Dec 06; 113(12):1290-5. PubMed ID: 24122718
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 06; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia.
    Kataoka Y, Harada-Shiba M, Nakao K, Nakashima T, Kawakami S, Fujino M, Kanaya T, Nagai T, Tahara Y, Asaumi Y, Hori M, Ogura M, Goto Y, Noguchi T, Yasuda S.
    J Clin Lipidol; 2017 Aug 06; 11(2):413-421.e3. PubMed ID: 28502498
    [Abstract] [Full Text] [Related]

  • 10. Effects of lipoprotein apheresis on PCSK9 levels.
    Julius U, Milton M, Stoellner D, Rader D, Gordon B, Polk D, Waldmann E, Parhofer KG, Moriarty PM.
    Atheroscler Suppl; 2015 May 06; 18():180-6. PubMed ID: 25936324
    [Abstract] [Full Text] [Related]

  • 11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 06; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 12. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep 06; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 13. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA.
    Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602
    [Abstract] [Full Text] [Related]

  • 14. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy.
    Raal F, Panz V, Immelman A, Pilcher G.
    J Am Heart Assoc; 2013 Apr 24; 2(2):e000028. PubMed ID: 23537802
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
    Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Inoue T, Mori M, Tada H, Nakanishi C, Yagi K, Yamagishi M, Ueda K, Takegoshi T, Miyamoto S, Inazu A, Koizumi J, Hokuriku FH Study Group.
    Atherosclerosis; 2014 Sep 24; 236(1):54-61. PubMed ID: 25014035
    [Abstract] [Full Text] [Related]

  • 20. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan 24; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.